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Abstract
Many studies have described the features of menstrually related migraines but there is a lack of knowledge regarding the 
features of migraine in combined hormonal contraceptive users (CHC). Hormone-withdrawal migraines in the pill-free 
period could differ from those in the natural cycle. Gynaecologic comorbidities, like dysmenorrhea and endometriosis, but 
also depression or a family history might modify the course of migraine. A better understanding of migraine features linked 
to special hormonal situations could improve treatment. For this prospective cohort study, we conducted telephone inter-
views with women using a CHC and reporting withdrawal migraine to collect information on migraine frequency, intensity, 
triggers, symptoms, pain medication, gynaecologic history and comorbidities (n = 48). A subset of women agreed to also 
document their migraines in prospective diaries. The mean number of migraine days per cycle was 4.2 (± 2.7). Around 50% 
of these migraines occurred during the hormone-free interval. Migraine frequency was significantly higher in women who 
suffered from migraine before CHC start (5.0 ± 3.1) (n = 22) in comparison to those with migraine onset after CHC start 
(3.5 ± 2.1) (n = 26). Menstrually related attacks were described as more painful (57.5%), especially in women with migraine 
onset before CHC use (72%) (p < 0.02). Comorbidities were rare, except dysmenorrhea. The majority of migraine attacks 
in CHC users occur during the hormone-free interval. Similar as in the natural cycle, hormone-withdrawal migraines in 
CHC users are very intense and the response to acute medication is less good, especially in those women, who developed 
migraine before CHC use.
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Abbreviations
CHC  Combined hormonal contraceptives
HFI  Hormone-free interval
ICHD  International Classification of Headache 
Disorders
MRM  Menstrually related migraine
PMM  Pure menstrual migraine
Background
Combined hormonal contraceptives (CHC) can trigger 
migraine onset or worsen the course of migraine [1–3]. A 
typical trigger for headache attacks is hormone withdrawal 
during the monthly hormone-free interval (HFI), which 
is also the time frame during which withdrawal bleeding 
occurs. To date there is little knowledge about characteris-
tics of migraine in CHC users in comparison to nonusers. 
It is also unknown, if migraine phenotypes differ between 
CHC users, who had their first migraine attacks prior to the 
initiation of CHC, or afterwards. The presence of associated 
gynaecologic comorbidities, like dysmenorrhoea and endo-
metriosis could also modify migraine features [4–9]. Severe 
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dysmenorrhea has a prevalence of around 20% and may be 
associated with endometriosis and chronic pelvic pain [4–7, 
9, 10]. Another well-known comorbidity of migraine and 
potential adverse event in a subset of CHC users is depres-
sion [11–13]. According to the ICHD-3 Appendix Menstru-
ally related migraines (MRM) are attacks on day 1 ± 2 of the 
menstruation in at least two of three cycles [14]. They are 
without aura. Migraine attacks occur also at other times of 
the menstrual cycle, while in women with pure menstrual 
migraine (PMM) attacks occur only at bleeding days 1 ± 2. 
Those definitions are not only used for the natural cycle but 
also for hormone withdrawal bleedings as those in the pill 
break of CHC users. However, a recent study demonstrated 
that in CHC users, migraine attacks in relation to bleeding 
occur most frequently on days − 1 to 4 [15]. While estrogen 
withdrawal is a major pathomechanism of hormone-with-
drawal headaches, if has been shown that continuous use 
of progestins can exert a positive impact on menstrual and 
non-menstrual migraines [16].
Hormone withdrawal in CHC users is much more abrupt 
in comparison with the smoother decline of hormones at the 
end of the natural cycle. Consequently, also the menstrually 
related migraines (MRM) in CHC users might differ with 
regard to onset, intensity, and response to pain medication 
from MRM in the natural cycle. A better understanding of 
migraine features in CHC users and awareness for gynae-
cological comorbidities might have an impact on treatment 
decisions regarding choice of prevention and the choice of 
hormones used to treat migraine attacks during the HFI. Pro-
gestins used in contraception can exert a positive impact on 
dysmenorrhea and endometriosis, but also on the course of 
migraine [17–20].
The present study was carried out to identify migraine 
features in women who use CHC and to compare these fea-
tures between individuals with migraine onset before or after 
first CHC use. Furthermore we aimed to select information 
on comorbidities like dysmenorrhea, endometriosis and 
depression, as well as on migraine onset, family history and 
age at menarche. The latter is frequently mentioned as a typi-
cal age associated with migraine onset. With the diary part 
of the study we aimed to compare migraine frequency, pain 
intensity, and use of pain medication in the three weeks of 
pill use and the HFI between both groups.
Methods
This prospective trial was conducted at the Clinic for 
Reproductive Endocrinology, University Hospital Zurich, 
where one of the authors (GSM) runs a clinic for hormonal 
migraine. Data for this convenience sample were collected 
from November 2017 to May 2019. We recruited partici-
pants in the clinic and through advertisement. Women were 
contacted by phone to explain the project and to screen 
for eligibility. Premenopausal women aged 18–50 years 
were included, if they had a history of MRM, as defined 
in the ICHD-3 during in at least two of three cycles and 
used any type of CHC with a monthly hormone-free period 
of 7 days (21/7 regimen). Women were included if they 
agreed to participate in an interview only or if they agreed 
to both, an interview and daily conducted diaries for three 
cycles. Exclusion criteria comprised CHC use in flexible or 
extended cycles, use of other hormones and migraine dur-
ing CHC use but not in the HFI. All women gave written 
informed consent.
Data were collected during a semi-structured telephone 
interview performed by two residents who are familiar with 
the International Classification of Headache Disorders 
(ICHD-3) under supervision of a senior gynaecological 
headache specialist (GSM) [14]. We aimed to perform 50 
complete interviews. We collected information on age at 
migraine onset, frequency, severity (numerical rating scale 
from 1 to 10), duration and localization of headaches, aura 
triggers, associated symptoms, family history as well as use 
of acute medication and prophylactic medication. Further-
more we explored comorbidities with a focus on depression, 
dysmenorrhea, endometriosis, and other chronic pain condi-
tions. Age at menarche, first start of use of a CHC and the 
type of CHC used at present were documented. All women 
were asked to conduct a prospective headache diary over 
three CHC cycles (84 days) to document migraine days, pain 
intensity and the amount of pain medication used during the 
HFI and during pill use. Additional diary data were used 
for a separate project [15]. The hormone-free days and days 
with uterine bleeding were also recorded. For the diaries, 
a simple pain score from 0 to 3 was used: 0 = no, 1 = mild, 
2 = moderate and 3 = severe pain in accordance with ICHD-3 
[14]. Diaries were send out per email and started on the first 
day of pill use. To facilitate comparison with the natural 
cycle, which starts with hormone withdrawal and bleeding 
we present our data starting with the HFI at days 1–7. Weeks 
2, 3, and 4 were the weeks with daily CHC use. Women, who 
had agreed to conduct a diary returned the diary per email 
after each cycle. All data were analysed for women with 
migraines onset before start of CHC (group 1) and migraines 
onset after having started CHC (group 2). The study has 
been approved by the regional ethics committee (KEK-stV-
Nr 2016-01791) and was registered on clinicaltrials.gov: 
NCT04012593.
Statistical analyses
The programmes IBM SPSS Statistics 22 and Excel 
2016 were used for statistical analyses. Continuous 
demographic and clinical characteristics were presented 
as means ± standard deviation (SD). Frequencies and 
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percentages were used to describe dichotomous character-
istics. If women answered a question with ‘I do not know’ 
this answer was not included in the analysis. Mann–Whit-
ney U Test or Fisher’s exact test were used to compare 
demographic data and characteristics between women 
with migraine already existing before CHC use (group 1) 
and women, whose migraine onset was after first use of 
CHC (group 2). In the subgroup of participants, who con-
ducted a daily diary migraine frequency, intensity (pain 
score 0–4) and number of pain medications are reported 
weekly during the HFI. For weeks 2–4, the mean values 
were divided by 3 to receive a weekly number for this 
period, which allows comparison with the one week HFI. 
Mean pain score was calculated as sum/week. Also here 
the value was divided by 3 to get a weekly mean value 
to allow comparison between the HFI and the phase of 
hormone use. p values ≤ 0.05 were considered as statisti-
cally significant.
Results
Among the 69 patients screened, 48 were eligible for the 
study and were interviewed. Out of thirty-nine women, who 
agreed to conduct a diary after the interview, 28 completed 
study diaries over three cycles (Fig. 1). Only three individu-
als had only menstrually related attacks i.e. pure menstrual 
migraine (PMM), while all others experienced in addition 
attacks during use of the CHC. The three persons with PMM 
were all in group 2. Their data were not included into the 
analyses of the first two questions in Table 2 (pain inten-
sity and response to pain medication in menstrually related 
attacks). Baseline characteristics are presented in Table 1 
and more detailed headache features, gynaecologic charac-
teristics and comorbidities in Table 2. Demographic data 
and baseline migraine features did not differ between women 
who participated in the interview only and those who also 
conducted the diary (Table 3).   
Mean age of the participants was 26.5 ± 5 years, mean 
age at the first migraine attack was 17.9 ± 5.7  years, 
Fig. 1  Flowchart: inclusion and 
exclusion process 69 paents screened for eligibility 
48 eligible for interview  
39 agreed to conduct diary  
28 completed migraine diaries over three cycles 
7 paents with other pill rhythm than 21/7 
5 paents with other contracepves than CHC (coil, gestagen only pill) 
2 paents with migraine aacks in less than 2 out of 3 months 
8 paents withdrew their consent or didn’t want to take part in the study 
6 paents with loss of contact or withdrawal of consent 
2 paents stopped CHC use
3 paents didn’t show signs of menstrual migraine or only in less than 2 out 
of 3 months in the diary 
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the mean age at the first menstrual bleeding was 
13.0 ± 1.2 years and the mean number of migraine days/
month was 4.2 ± 2.7. Nineteen percent of patients reported 
a history of more than one auras. In comparison to women 
who developed their migraine after start with CHC (group 
2 n = 26), women with migraine before CHC start (group1 
n = 22) were younger at migraine onset, suffered less 
frequently from dysmenorrhoea and had more monthly 
migraine days (Table 1). They also reported more often 
a positive family history (FH) for migraine (Table 2). 
Table 1  Comparison of demographic and clinical characteristics of patients with migraine existing before start with combined hormonal contra-
ception (CHC) (group 1) and women whose migraine started after having initiated CHC (group 2)
*Questions answered with: I do not know, or I do not remember were excluded from the final analyses
Characteristics* All n = 48 Group 1 n = 22 Group 2 n = 26 p value
Age (years) mean (SD) 26.5 (5.0) 28.6 (6.3) 27.3 (4.4) 0.29
Size (cm) mean (SD) 165 (5.3) 164 (6.0) 166 (5.0) 0.2
Weight (kg) mean (SD) 60.3 (14.3) 58.1 (16.0) 62.2 (13.0) 0.049
Age at first menstruation (year) mean (SD) 13.0 (1.2) 12.7 (1.2) 13.2 (1.19 0.13
Age at first migraine attack (year) mean (SD) 17.9 (5.7) 14.2 (4.9) 21.0 (4.4) 0.001
Ages at first start with CHC mean (SD) 17.4 (2.7) 16.7 (1.4) 18.8 (3.5) 0.39
Number of migraine days/months at age < 20 years mean (SD) 1.9 (2.4) 2.3 (2.5) 1.6 (2.3) 0.03
Number of migraine days/months now mean (SD) 4.2 (2.7) 5.0 (3.1) 3.5 (2.1) 0.048
Pain score of attacks on a scale of 1–10 mean (SD) 6.5 (1.6) 6.4 (1.9) 6.7 (1.3) 0.78
Migraine with aura: yes n (%) 9 (18) 4 (18) 5 (19) 0.98
Aura only once n (%) 31 (64) 14 (63) 17 (65) 0.53
Duration of attacks (h) mean (SD) 27.7 (34.9) 25.2 (30.0) 29.8 (38.8) 0.86
Dysmenorrhoea % (n) 75.0 (36) 63.6 (14) 84.6 (22) 0.049
Smoking: yes % (n) 3.8 (8) 1.3 (6) 0,5 (2) 0.07
Sport: h/week mean (SD) 3.2 (2.6) 3.6 (3.0) 2.7 (2.1) 0.51
Table 2  Migraine features and clinical characteristics of patients with migraine existing before start with combined hormonal contraception 
(CHC) (group 1) and women whose migraine started after having initiated CHC use (group 2)
*Three participants from group 2 with PMM were excluded from this analysis
Migraine feature n All n = 48 Group 1 n = 22 Group 2 n = 26 p value
Menstrually related attacks are more painful than others* % (n) 57.5 (26) 72.7 (16) 43.4 (10) 23n 0.015
Menstrually related attacks respond good to pain medication* % (n) 47.8 (22) 31.8 (7) 65.2 (15) 0.05
Pain location: unilateral mostly or always % (n) 95.1 (39) 95 (19) 95,2 (20) 0.99
Family history positive % (n) 72.9 (35) 86.4 (19) 61.5 (16) 0.05
Medication overuse headache in the past % (n) 10.4 (5) 10.0 (2) 11.5 (3) 0.62
Status migrainosus ever % (n) 41.7 (20) 47.6 (10) 38.5 (10) 0.42
Triptan use as acute medication % (n) 40.9 (18) 27 (5) 54.2 (13) 0.04
Ever use of prophylactic agents % (n) 8.9 (6) 3.2 (1) 19.2 (5) 0.76
Non-hormonal trigger yes % (n) 81.1 (39) 81.8 (18) 80.8 (21) 0.61
Associated symptoms % (n) 87.5% (42) 86.4 (19) 88.5 (23) 0.58
Nausea % (n) 62.5 (30) 54.5 (12) 69.0 (18) 0.22
Vomiting % (n) 29.2 (14) 18.2 (4) 38.5 (10) 0.20
Photophobia % (n) 64.6 (31) 63.6 (14) 65.4 (17) 0.57
Phonophobia % (n) 45.8 (22) 36.4 (8) 53.8 (14) 0.26
Endometriosis % (n) 0 (0) 0 (0) 0 (0) 0.99
Depression % (n) 4.3% (2) 0 (0) 7.7 (2) 0.31
Other types of chronic pain % (n) 4.3% (2) 0 (0) 7.6 (2) 0.41
History of traumatic brain injury, meningitis, concussion % (n) 0 (0) 0 (0) 0 (0) 1.0
History of stroke % (n) 0 (0) 0 (0) 0 (0) 1.0
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Furthermore a higher percentage of individuals in group 
1 experienced MRM as more painful and less responsive to 
rescue medication. Interestingly, the percentage of triptan 
users was nevertheless lower in comparison to group 2. 
Diary data confirmed the total number of migraine days/
month (4.11 ± 2.8) and showed a trend to a higher fre-
quency in group 1 (p < 0.07). The weekly pain score 
differed between groups only during the HFI (p < 0.02) 
(Table 4). In addition there was a trend towards a higher 
number of migraine days (p < 0.06) and pain medications 
used during this period (p < 0.07) for group 1.
Among the most frequent non-hormonal triggers were 
stress (58.3%), sleep deficiency (35.4%) and weather 
changes (18.8%). Less than 10% of the individuals men-
tioned odours, long working time spend at a computer 
screen or hunger. The subgroups did not differ with regard 
to migraine triggers or associated symptoms. Associated 
symptoms reported from more than 10% of the participants 
comprised nausea, vomiting photophobia and phonophobia 
(Table 2). Only six women had ever used a prophylactic 
substance, mostly (n = 5) in form of riboflavin or magnesium 
or both. Only one person had a history of a pharmacological 
prophylaxis, topiramate.
None of the interviewed participants had a history of 
meningitis, traumatic brain injury, or concussion.
Apart from dysmenorrhoea, migraine associated medical 
conditions were rare in both groups of young women (no 
endometriosis, two women with a history of depression).
Migraine onset occurred within ± 2 years in relation to 
menarche in 63% of the women in group 1. Within CHC 
users who had not experienced migraine earlier 38.5% 
experienced the onset of migraine within 2 years and 57.7% 
within 4 years after start of this contraceptive method.
Discussion
Interview data demonstrated, that most migraine days in 
CHC users occurred during the HFI. Around 50% of CHC 
users report, that these menstrually related migraines are 
more painful than other migraine attacks and respond less 
good to pain medication. Interestingly, migraine features and 
family history differed between individuals who already suf-
fered from migraine before starting a CHC (group 1) and 
those who developed it after the initiation of CHC (group 2). 
Women in group 1 reported a higher frequency of monthly 
migraine days more painful menstrually related attacks, 
inferior response to pain medication, a higher pain score 
and use of more pain medication in the hormone-free week. 
Also, a positive family history for migraine was more com-
mon in group 1. In the diaries the pain score, the number of 
migraine days and the number of days with pain medication 
were higher in the HFI for the total group and within the 
two subgroups in comparison with the weeks of pill intake.
In accordance with our data, trials comparing menstrual 
and non-menstrual migraine report consistently, that MRM 
Table 3  Comparison of demographic data and migraine characteristics in women participating in the interview only and participating in the 
interview and diary part of the study
Characteristic Interview only n = 20 Responders diary and inter-
view n = 28
p
Age (years) mean (SD) 27.1 (5.2) 27.9 (5.3) 0.74
Size (cm) mean (SD) 166.6 (4.9) 165.1 (5.9) 0.32
Weight (kg) mean (SD) 61.5 (16.7) 59.3 (12.8) 0.45
Smoking number daily mean (SD) 0.5 (1.3) 0.29 (0.9) 0.54
Sport/h/week mean (SD) 3.6 (3.0) 2.8 (2.2) 0.31
Migraine before CHC start % (n) 45 (9) 46.4 (13) 0.87
Age at first menstruation (year) mean (SD) 12.9 (1.3) 13.1 (1.1) 0.46
Age at first migraine attack (year) mean (SD) 17.8 (5.4) 18.0 (6.0) 0.93
Number of migraine days/months at age < 20 years mean (SD) 2.0 (2.4) 1.8 (2.4) 0.62
Number of migraine days/months now mean (SD) 4.1 (3.1) 4.2 (2.4) 0.85
Pain score of attacks on a scale of 1–10 mean (SD) 6.1 (1.9) 6.9 (1.3) 0.23
Are menstrual attacks more painful % (n) 52.6 (10) 57.1 (16) 0:79
Migraine with aura: yes % (n) 100 (20) 100 (27) 0.71
Aura only once % (n) 80 (12) 68 (19) 0.68
Duration of attacks (h) mean (SD) 21.8 (19.4) 29.8 (34.7) 0.31
Dysmenorrhoea % (n) 78.9 (15) 75.0 (21) 0.92
Pain unilateral always or mostly % (n) 94.7 (18) 95.5 (21) 0.91
Family history for first- or second-degree relative yes % (n) 65.0 (13) 67.9 (19) 0.23
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are more severe, of longer duration and more resistant to 
treatment compared to non-menstrual attacks [21–25]. Up 
to date, it was not clear if hormone withdrawal migraines in 
CHC users have the same characteristics. Based on diaries 
conducted over 2 months, Coffee et al. did not find any dif-
ference in daily headache scores in 21 CHC users, but did 
not distinguish non-MRM and MRM [26]. In another trial, 
55% of 20 CHC users with pure menstrual migraine, rated 
their attacks as severe [27]. It is unclear, if women in this 
trial had already suffered from migraine before the initiation 
of hormonal contraception. In a large retrospective cohort 
study, a similar percentage (52.3%) of hormonal contracep-
tive users reported a worsening of migraine in temporal rela-
tion to the menstrual bleeding [28]. This is in line with our 
finding of 57% women describing MRM as more painful. 
Notably this percentage was significantly higher in women 
with migraine before CHC start (73%). The overall pain 
score reported in the interviews for all migraines did not 
differ between groups.
In our study, the mean age at the first migraine attack was 
17.9 years and significantly lower (14.2 years) in women 
who developed migraine before CHC start. In other trials 
on hormonal migraines, this age ranges from 16 to 25 years. 
No information is given on the age at menarche [29–32]. 
The mean age of our participants was low (26.5 years) in 
comparison to other studies on MRM, which might reduce 
the risk of recall bias concerning the age at menarche and 
the age at the first migraine attack [24, 27, 32, 33]. In group 
2, the mean time frame between CHC start and migraine 
onset was 2.2 years. Insofar it is open in how many women 
a causal relationship between CHC use and migraine onset 
exists.
Onset of migraine had occurred within 2 years before or 
after menarche in 63% of the individuals of group 1. We pre-
sent data in this 2-year interval, as the hypothalamic–pitui-
tary system starts to release first irregular impulses and later 
more regular impulses already around two years prior to the 
first bleeding [34]. Our data indicate that many, but by far 
not all, hormone-related migraines start in this period with 
the most relevant hormonal alterations during puberty. In 
a survey including 80 women (mean age 33.6 years) with 
episodic migraine around 50% indicated that migraine onset 
had occurred within 1 year after menarche [33]. In our study, 
only two of 15 women reported migraine onset in this time 
span. Difficulties to recall age at the first menstruation up 
to 20 years later might at least partly explain the differences 
to our results.
Despite the difference in mean age compared to other 
trials (35.3 years; 38.3 years), the frequency of migraine 
days/month in our trial with CHC users (4.2) was similar to 
that in other reports (4.4 and 5.0) investigating MRM [30, 
32]. Migraine frequency was, however, significantly higher 
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frequency was twofold compared with the frequency 
reported below the age of 20 years. From our study design, 
it cannot be inferred, if there this is a physiologic age-related 
increase in migraine days or to some extent a causal relation-
ship with CHC use. A rapid age-related doubling of migraine 
frequency does not seem to be very probable given the data 
on migraine frequency and age in the two aforementioned 
studies. However, having 1–2 more migraine days per month 
can be related to increased disability, if those migraine days 
cannot be treated successfully. Especially if these are attacks 
in the HFI. The diary data confirmed, that the pain score 
in this week is especially high (p < 0.001) and even more 
high in group one (p < 0.02). In respect of migraine aura, 
we did not see differences between both groups (Table 1). 
This suggests, that the predisposition to migraine aura is not 
influenced by the intake of CHC. However, it is striking that 
patients with possible migraine aura are still prescribed CHC 
despite the potential risk of thromboembolic events [35, 36]. 
We would suggest that gynecologists should actively ask 
for migraine aura prior to discussing contraception with 
their patients. Estrogen-containing contraceptives should 
be avoided in patients with migraine aura.
Eighty-six percent of the individuals in group 1 had a 
positive family history for migraine, which is in line with 
findings from epidemiologic studies demonstrating an 
association of a positive family history with an early onset 
of migraine [37, 38]. Furthermore, depression was found 
in 57% of the migraineurs with FH. In our trial only two 
women reported to have experienced a depressive episode in 
the past. None of them had used antidepressants. Psychiat-
ric disorders and musculoskeletal disorders are significantly 
more common in patients with chronic than in those with 
episodic migraines. Older age and longer duration of disease 
have an impact on the prevalence of the comorbidities, what 
explains the low rate of this conditions in our trial [39]. A 
history of dysmenorrhoea was reported by 76.6% of women 
in our study. This percentage was even higher in group 2, in 
which on the other hand fewer women had a positive family 
history. Spierings et al. found in women with menstruation-
sensitive migraine that 43.8% suffer from dysmenorrhoea 
and 10% from endometriosis [33]. Dysmenorrhoea is more 
frequent in younger women. In an Australian survey, 93% 
of teenagers aged 16–18 years experienced some degree of 
pain during menstruation. Insofar the numbers in our study 
regarding this comorbidity are in the range of young women 
without migraine. In the same Australian survey, evaluat-
ing comorbidities of dysmenorrhea, stabbing pelvic pain 
was associated with migraine (OR of 2.3). About one-fifth 
(21.1%) of the responders with dysmenorrhoea reported 
headaches on 15 or more days per month [4]. The severity 
of dysmenorrhea was not quantified in our study and use of 
CHC users is typically associated with reduced pain severity 
of dysmenorrhea. Endometriosis had not been diagnosed in 
any of our participants. Nevertheless, a subset of the women 
in our study suffering from dysmenorrhea might have this 
condition.
In both groups, most migraine attacks were described as 
unilateral. Triptan use was more frequent in group 2, also 
migraine intensity did not differ between groups. Further-
more, in group 1, only one person had ever tried to use pro-
phylactic substances, while this was the case in five persons 
of group 2. It can only be speculated that migraineurs of 
group 1 might have developed better coping strategies dur-
ing their longer history of migraine or by having taken fam-
ily members as role models [40].
Migraine triggers were reported by about 80% of the par-
ticipants, which is similar to the 76% of migraineurs report-
ing triggers in a study with 1750 women suffering from 
episodic headache [41]. In line with other studies, stress 
and sleep deficiency were by far the mostly reported trigger 
[42–44]. No difference was found between the groups.
Associated symptoms were frequent (87%) and did not 
differ between groups. The frequency is in congruence with 
findings from other authors for MRM in not CHC users [29, 
30, 32].
Altogether we found in our sample that most migraine 
days in CHC users occur during the HFI. Migraines are 
mostly unilateral and triggers do not differ from those 
reported from other authors for episodic migraine. The men-
strually related attacks are more painful and less responsive 
to acute pain medication. Therefore gynaecologists and 
neurologists should discuss other contraceptive options, 
like modern progestin-only pills, which would also have 
a positive impact on dysmenorrhoea and a potentially not 
yet diagnosed endometriosis. The group of young women 
with migraine before CHC use reporting earlier migraine 
onset, higher migraine frequency, higher pain scores and 
a stronger family predisposition might belong to a distinct 
clinical entity. These persons should even more be advised 
to use a contraceptive with rather a beneficial effect on their 
migraines, like the progestin desogestrel [19, 45, 46]. Our 
data did not allow to clarify, if the considerable increase in 
migraine days after age twenty might indeed be related to 
the use of CHC or if this rather corresponds to the natural 
course of migraines in these young women.
Strength and limitations
A limitation of this project is the sample size, which is 
smaller as compared to web-based surveys or surveys using 
self-completed questionnaires without any instruction for the 
individuals enrolled. Our sample size is within the range of 
that of other interview and diary-based studies addressing 
migraine features [21, 27, 29, 30, 33, 47, 48]. A strength 
is, that the interview data were collected from experi-
enced headache specialists, insofar a higher correctness of 
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responses can be expected in comparison with self-com-
pleted questionnaires or online surveys. In addition a bias 
by misunderstanding questions is unlikely. Furthermore, the 
high percentage of women who recorded headache charac-
teristics in prospective daily diaries contributes to the qual-
ity of the data. The number of migraine days did not differ 
between women participating solely in the interview and 
those keeping a prospective diary over three cycles. The 
diaries over 3 months confirmed the diagnosis of MRM in 
at least two of three cycles. The strict inclusion/exclusion 
criteria, checked by a skilled doctor reduced the number 
of eligible women but contributed to a higher validity. For 
group 2, it remains open, if the use of CHC is the reason 
why these women developed a migraine. Strengths of the 
study include the exact definition of the type of hormonal 
contraception used, the exclusion of progestin-only methods 
or hormone-releasing-intrauterine devices and the inclusion 
of women only with withdrawal headache in at least two of 
three cycles as required in the ICHD. In addition we ensured, 
that results are not biased by women suffering from post-
traumatic or post-inflammatory headaches.
Conclusion
Migraines in CHC users occur mostly in the hormone-free 
interval. They are typically unilateral and associated symp-
toms and triggers do not differ from those described by other 
authors. The MRM during the HFI are also in CHC users 
more intense and less responsive to acute medication. This 
is more pronounced in women with early migraine onset, 
a positive family history and migraine before use of CHC. 
The frequency of typical comorbidities was low except for 
dysmenorrheoa.
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